SCHEMBL9605514

SCHEMBL9605514

Cc1nc2ccccc2n1-c1ccc(C#N)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.54
HTT P42858 2/20 0.54
TSHR P16473 2/20 0.44
PDE4B Q07343 2/20 0.43
PDE4D Q08499 2/20 0.43
ALDH1A1 P00352 5/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GAA P10253 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 2/20 0.41
HCRTR1 O43613 1/20 0.39
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 2/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL540942 0.77 MAPK1 (0.68) MAPK1HTTTSHRALDH1A1HPGD
SCHEMBL22507416 0.75 MAPK1 (0.74) MAPK1HTTTSHRALDH1A1KDM4E
SCHEMBL10041256 0.75 MAPK1 (0.79) MAPK1HTTTSHRALDH1A1KDM4E
SCHEMBL13030954 0.75 HTT (0.79) MAPK1HTTTSHRALDH1A1KDM4E
SCHEMBL22507417 0.75 MAPK1 (0.68) MAPK1HTTTSHRALDH1A1HPGD
SCHEMBL20881962 0.75 TSHR (0.64) MAPK1HTTTSHRALDH1A1KDM4E
SCHEMBL17694823 0.74 MAPK1 (0.67) MAPK1HTTTSHRALDH1A1HPGD
SCHEMBL22507480 0.74 HTT (0.67) MAPK1HTTTSHRALDH1A1KDM4E
SCHEMBL16122597 0.74 MAPK1 (0.50) MAPK1HTTTSHRALDH1A1HPGD
SCHEMBL23245562 0.74 TRPV4 (0.47) MAPK1PDE4BPDE4DALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835445-B2 Dihydrofolate reductase inhibitors TRIUS THERAPEUTICS, INC. (US) 2014-09-16 US disclosed
US-20120136014-A1 DIHYDROFOLATE REDUCTASE INHIBITORS TRIUS THERAPEUTICS, INC. (US) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136014-A1 DIHYDROFOLATE REDUCTASE INHIBITORS DHFR, DPYD, DHODH MAPK1 1582/4885HTT 2141/4885TSHR 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.